TMX Newsfile·2026-01-31 23:34Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][7]. - The lead plaintiff must file a motion with the Court by March 16, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder [5]. - Defendants reportedly made overly positive statements about the drug's trial success while concealing adverse facts about the Phase 3 PALISADE-3 trial [6].